The latest price target for Anebulo Pharmaceuticals (NASDAQ:ANEB) was reported by Maxim Group on July 23, 2025. The analyst firm set a price target for $0.00 expecting ANEB to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Anebulo Pharmaceuticals (NASDAQ:ANEB) was provided by Maxim Group, and Anebulo Pharmaceuticals downgraded their hold rating.

There is no last upgrade for Anebulo Pharmaceuticals

The last downgrade for Anebulo Pharmaceuticals Inc happened on July 23, 2025 when Maxim Group changed their price target from N/A to N/A for Anebulo Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anebulo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anebulo Pharmaceuticals was filed on July 23, 2025 so you should expect the next rating to be made available sometime around July 23, 2026.

While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a downgraded with a price target of $0.00 to $0.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $2.30, which is out of the analyst’s predicted range.